Discover the groundbreaking role of PCSK9 in cardiometabolic aging and its promising future as a therapeutic target and biomarker in the dynamic field of vascular neurosurgery.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
PCSK9: an emerging player in cardiometabolic aging and its potential as a therapeutic target and biomarker.
Csiszar et al., Geroscience 2023
DOI: 10.1007/s11357-023-01003-0
New Insights into PCSK9’s Role in Cardiometabolic Aging
The review highlights the expanding role of Proprotein convertase subtilisin/kexin type 9 (PCSK9) beyond its established function in cholesterol metabolism, emphasizing its significance in the aging of cardiovascular and metabolic systems. The work builds on the foundation laid by Arif et al. from the Pacher laboratory, which has been instrumental in uncovering PCSK9’s impact on the aging heart and liver.
Key points of interest include:
- PCSK9’s influence on liver aging and the potential links between hepatic aging, lipid metabolism, and cardiovascular health.
- The exploration of PCSK9 as a therapeutic target and biomarker for age-related cardiovascular diseases.
This review is important as it broadens the understanding of PCSK9’s role in cardiometabolic health and its potential as a therapeutic target. It contributes to the current literature by connecting PCSK9 with the aging process, which could lead to novel interventions for age-associated diseases.